NCT02716675: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02716675 |
|---|---|
| Title | A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | April 6, 2016 |
| Completion date | Dec. 1, 2020 |
| Required reporting date | Dec. 1, 2021, midnight |
| Actual reporting date | Nov. 23, 2021 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |